ACR Convergence 2025| Tips for Starting Your Own Rheumatology Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Lupus nephritis"

A Liquid Biopsy for Lupus Nephritis?

Samantha C. Shapiro, MD  |  October 10, 2025

Urine biomarkers have the potential to change how lupus nephritis is managed, serving as a noninvasive means of early detection, assessing treatment response and more.

Study: Reducing Cardiovascular Risks Helps Lupus Patients

Deborah Levenson  |  October 8, 2025

Long-term remission & control of CVD risk factors can reduce the risk of atherosclerosis in lupus; triple APL positivity raises the risk of CVD, study finds.

Rethinking Lupus Nephritis: Are Current Approaches & Guidelines off Target?

Mithu Maheswaranathan, MD  |  September 9, 2025

A rheumatologist & lupus expert reviews lupus nephritis treatment, questioning proteinuria cutoffs & ACR guidelines, advocating for newer therapies & end-of-treatment biopsies.

B Original: B Cells, Non-Invasive Biomarkers & More

Jason Liebowitz, MD, FACR  |  July 15, 2025

Experts discussed how aspects of the immune system other than B cells play a role in lupus, including mitochondria in red blood cells, proteins present in urine and more.

Lupus Nephritis: A Brief Review

Keri Losavio  |  May 15, 2025

Among patients with sys­temic lupus erythematosus (SLE), lupus nephritis is one of the more common health problems and a leading cause of mortality. In adults with SLE, as many as five of 10 will develop kidney disease. In children with lupus, eight of 10 will develop kidney disease.1 Lupus nephritis appears to be more prevalent…

lupus nephritis, showing wire loop and hyaline thrombi, PAS stain, magnification 400x, photo under microscope

Lupus Nephritis Guideline Encourages Triple Therapy

Ruth Jessen Hickman, MD  |  November 24, 2024

Screening recommendations, triple therapy and more—here are insights into the upcoming ACR guideline for the care and treatment of patients with lupus nephritis.

Autoantibodies Illuminate Lupus Nephritis

Arthritis & Rheumatology  |  October 28, 2024

Fava et al. investigated longitudinal autoantibody profiles in patients with lupus nephritis (LN) to define serological biomarkers of histologic class. They found that baseline levels of anti-C1q and anti-double-stranded DNA antibodies may serve as noninvasive biomarkers of proliferative LN and anti-C1q antibodies may predict complete response.

Lupus Update: Findings from the Latest Phase 3 Clinical Trials

Michele B. Kaufman, PharmD, BCGP  |  October 11, 2024

Two new treatment studies among patients with systemic lupus erythematosus and lupus nephritis had promising results.

Glucocorticoids Increase Infections, Mortality

Arthritis & Rheumatology  |  August 19, 2024

Figueroa-Parra et al. set out to evaluate the effect of glucocorticoid regimens on renal response, infections and mortality rates among patients with lupus nephritis (LN). The researchers analyzed the control arms of randomized clinical trials and found a higher exposure to glucocorticoids during the initial treatment of LN was associated with better renal outcomes, at the cost of increased infections and mortality.

FDA Updates Safety & Efficacy Information for Voclosporin

Michele B. Kaufman, PharmD, BCGP  |  July 10, 2024

The FDA’s latest label change for voclosporin adds data demonstrating its safety and efficacy, as well as a sustained renal response, in patients with lupus nephritis through three years of treatment.

  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences